JP2022105084A5 - - Google Patents

Download PDF

Info

Publication number
JP2022105084A5
JP2022105084A5 JP2022072043A JP2022072043A JP2022105084A5 JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5 JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022072043 A JP2022072043 A JP 2022072043A JP 2022105084 A5 JP2022105084 A5 JP 2022105084A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disease
acid sequence
amino acid
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022072043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022105084A (ja
JP7403575B2 (ja
Filing date
Publication date
Priority claimed from JP2022051047A external-priority patent/JP7391132B2/ja
Application filed filed Critical
Publication of JP2022105084A publication Critical patent/JP2022105084A/ja
Publication of JP2022105084A5 publication Critical patent/JP2022105084A5/ja
Priority to JP2023209102A priority Critical patent/JP7823011B2/ja
Application granted granted Critical
Publication of JP7403575B2 publication Critical patent/JP7403575B2/ja
Priority to JP2025174910A priority patent/JP2026012786A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022072043A 2015-03-09 2022-04-26 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法 Active JP7403575B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023209102A JP7823011B2 (ja) 2015-03-09 2023-12-12 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2025174910A JP2026012786A (ja) 2015-03-09 2025-10-16 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09
US62/130,076 2015-03-09
JP2022051047A JP7391132B2 (ja) 2015-03-09 2022-03-28 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022051047A Division JP7391132B2 (ja) 2015-03-09 2022-03-28 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023209102A Division JP7823011B2 (ja) 2015-03-09 2023-12-12 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Publications (3)

Publication Number Publication Date
JP2022105084A JP2022105084A (ja) 2022-07-12
JP2022105084A5 true JP2022105084A5 (https=) 2022-11-22
JP7403575B2 JP7403575B2 (ja) 2023-12-22

Family

ID=55863122

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2017547456A Pending JP2018509413A (ja) 2015-03-09 2016-03-08 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2021016293A Active JP7050191B2 (ja) 2015-03-09 2021-02-04 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2022051047A Active JP7391132B2 (ja) 2015-03-09 2022-03-28 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2022072043A Active JP7403575B2 (ja) 2015-03-09 2022-04-26 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2023209102A Active JP7823011B2 (ja) 2015-03-09 2023-12-12 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2025174910A Pending JP2026012786A (ja) 2015-03-09 2025-10-16 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017547456A Pending JP2018509413A (ja) 2015-03-09 2016-03-08 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2021016293A Active JP7050191B2 (ja) 2015-03-09 2021-02-04 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2022051047A Active JP7391132B2 (ja) 2015-03-09 2022-03-28 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023209102A Active JP7823011B2 (ja) 2015-03-09 2023-12-12 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法
JP2025174910A Pending JP2026012786A (ja) 2015-03-09 2025-10-16 ＦｃＲｎアンタゴニストを用いてＦｃ含有剤の血清レベルを低下させる方法

Country Status (19)

Country Link
US (1) US20160264669A1 (https=)
EP (2) EP3268391B1 (https=)
JP (6) JP2018509413A (https=)
KR (1) KR102720769B1 (https=)
AU (2) AU2016230827B2 (https=)
CA (1) CA2978253A1 (https=)
DK (1) DK3268391T3 (https=)
EA (1) EA038178B1 (https=)
ES (1) ES2882999T3 (https=)
HU (1) HUE056775T2 (https=)
IL (2) IL295425A (https=)
LT (1) LT3268391T (https=)
MX (2) MX386491B (https=)
MY (1) MY188761A (https=)
PL (1) PL3268391T3 (https=)
PT (1) PT3268391T (https=)
SG (2) SG10201908259WA (https=)
WO (1) WO2016142782A1 (https=)
ZA (1) ZA202109042B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
RS64768B1 (sr) * 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
WO2020148336A1 (en) * 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
WO2021016571A2 (en) * 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
AU2021292200A1 (en) * 2020-06-17 2023-02-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
JP7755725B2 (ja) * 2021-08-13 2025-10-16 ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド Ｆｃｒｎを特異的に認識する抗体およびその使用
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
CN120344557A (zh) * 2022-11-14 2025-07-18 阿根思有限公司 Fcrn拮抗剂分子及其使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002043658A2 (en) 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
WO2002040047A2 (en) 2000-11-20 2002-05-23 Canadian Blood Services Method for treating thrombocytopenia with monoclonal ivig
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE483472T1 (de) 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CA2512974A1 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
AU2012328819B2 (en) * 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
US20140302028A1 (en) * 2011-11-18 2014-10-09 Merck Sharp & Dohme Corp. Fc containing polypeptides having increased anti-inflammatory properties and increased fcrn binding
JP6285923B2 (ja) 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
SG11201605203UA (en) * 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
CA2978253A1 (en) * 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists

Similar Documents

Publication Publication Date Title
JP2022105084A5 (https=)
JP2017501725A5 (https=)
JP2018509413A5 (https=)
JP2025504815A5 (https=)
JP2025520420A5 (https=)
ES2823950T3 (es) Moléculas con especificidad para CD45 y CD79
JP5581323B2 (ja) ヒトｉｌ１７に対する抗体およびその使用
RU2005134394A (ru) Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа
US11421030B2 (en) BTLA antibodies
JP2016527187A5 (https=)
CA3258002A1 (en) FCRN BINDING MOLECULES AND METHODS OF USE
CA3034480A1 (en) Antibodies against signal-regulatory protein alpha and methods of use
US20080227704A1 (en) CXCL13 binding proteins
CN112154156A (zh) 抗cd38抗体的皮下给药
JP2018522578A (ja) ヒト化型親和性成熟抗ＦｃＲｎ抗体
JP2024530152A5 (https=)
JP2018524007A (ja) Ｃｄ２２に結合する抗体分子
WO2010055366A4 (en) Anti-human il-21 monoclonal antibodies
JP2018529313A (ja) Ｃｄ７９に結合する抗体分子
JP7688805B2 (ja) 二重特異性抗体
JP2022521850A5 (https=)
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease
JPWO2016021621A1 (ja) 新規抗ヒトＩｇβ抗体
TWI790617B (zh) 抗硬骨素抗體、其抗原結合片段及其醫藥用途
JP2025507836A (ja) 骨髄コンディショニング方法